Fundraising Fox

Longevity Series C Investors & VC Firms

49 firms in this list, with a median first check of $1M. 12 of them lead rounds. Generated from verified public data and updated continuously.

OrbiMed
New YorkPre-Seed–Late Stage$1M – $75M
126 people
GV (Google Ventures)
Mountain ViewSeed–Late Stage$250K – $50M
72 people
Foresite Capital
LarkspurPre-Seed–Late Stage
59 people
Portfolia
San MateoSeed–Late Stage
58 people
SV Health Investors
BostonPre-Seed–Late Stage$1M – $20M
29 people
Alumni Ventures
ManchesterPre-Seed–Late Stage$100K – $10M
28 people
Obvious Ventures
San FranciscoPre-Seed–Late Stage$250K – $6M
48 people
Basecamp Fund
ManchesterPre-Seed–Late Stage$100K – $10M
19 people
Catalio Capital Management, LP
New YorkSeed–Late Stage
41 people
LIFTT
TorinoPre-Seed–Late Stage
35 people
Novo Holdings
CopenhagenPre-Seed–Late Stage$1.1M – $54M
42 people
Advent Life Sciences
LondonSeed–Late Stage
29 people
MPM BioImpact
BostonPre-Seed–Series C$1M – $15M
40 people
Type One Ventures
Los AngelesPre-Seed–Late Stage$100K – $5M
21 people
EQT Life Sciences
LuxembourgSeed–Late Stage$11M – $66M
39 people
Casdin Capital
New YorkSeed–Series C
39 people
Ahren Innovation Capital
Cambridge, CambridgeshirePre-Seed–Late Stage
30 people
HealthCap
StockholmSeed–Growth
30 people
aMoon
Ra'ananaSeed–Late Stage
25 people
Lumira Ventures
TorontoPre-Seed–Late Stage$1M – $10M
17 people
K2 HealthVentures
BostonSeries A–Late Stage$10M – $100M
22 people
Alta Partners
JacksonSeed–Growth$1M – $12M
10 people
Pontifax Venture Capital
HerzeliyaPre-Seed–Late Stage$6.3M – $128M
8 people
Hadean Ventures
OsloSeed–Growth
21 people

Related lists

Data sourced from public filings and firms' own websites — see our methodology.